Clinical trial · Observational
the Real World Study of Orelabrutinib in the Treatment of CLL/SLL
A Retrospective Real-world Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT05975164CI-TRIAL-00068483unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Multicenter, Retrospective Real-world Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CLL/SLL | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall Response Rate (ORR)
- timeFrame
- up to two years
- description
- The ORR will be calculated as the proportion of participants who achieve either complete response (CR), partial response (PR) or partial response with lymphocytosis, as assessed by the participating physician.
Secondary outcomes (4)
- measure
- Time to Next Therapy (TTNT)
- timeFrame
- up to two years
- description
- The TTNT will be calculated as the difference betweenorelabrutinib initiation date and initiation date of the first next therapy for CLL
- measure
- Progression Free Survival (PFS)
- timeFrame
- up to two years
- description
- PFS is defined as the duration from date of orelabrutinib initiation to date of disease progression (PD \[according to the physician's evaluation\]) or death from any cause
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥18 years old 2. Patients with a definite diagnosis of CLL/SLL 3. Prior or current use of orelabrutinib for ≥3 months 4. At least one follow-up was recorded during orelabrutinib treatment Exclusion Criteria: 1.Patients who received orelabrutinib in a prospective clinical trial
References
Publications (0)
Data not yet available
No reference posted for this study.